Psilocybin: The most effective moral bio-enhancer?

Bioethics

Center for the Study of Bioethics, University of Belgrade, Belgrade, Serbia.

Published: September 2023

This paper addresses the possible effects of psychedelic drugs, notably psilocybin, on moral bio-enhancement (MBE). It will be argued that non-psychedelic substances, such as oxytocin, serotonin/serotonin reuptake inhibitors, or vasopressin, have indirect effects on M(B)E, whereas psilocybin has direct effects. Additionally, morality and happiness have been shown to operate in a circularly supportive relationship. It will be argued that psilocybin also has more direct effects on the augmentation of human happiness than non-psychedelic substances. Hence, psilocybin multiplies its effects on morality and on moral enhancement (as well as on happiness) if compared with non-psychedelic substances. Still, caution is advised if psilocybin is being used, and the correct dosage should be prescribed by an appropriate physician. Furthermore, the use of psilocybin has additional effects on moral enhancement and happiness if combined with meditation, preferably under the guidance of an experienced meditation specialist.

Download full-text PDF

Source
http://dx.doi.org/10.1111/bioe.13196DOI Listing

Publication Analysis

Top Keywords

non-psychedelic substances
12
will argued
8
psilocybin direct
8
direct effects
8
moral enhancement
8
psilocybin
7
effects
6
psilocybin effective
4
moral
4
effective moral
4

Similar Publications

Introduction: Substance use disorders (SUDs) are a public health issue, with only some having FDA-approved indicated treatments and these having high attrition. Consequently, there has been interest in novel interventions (e.g.

View Article and Find Full Text PDF

Despite psychedelic microdosing being a growing practice, the research on the topic is still in its infancy. While several studies have described the characteristics, motivations and practices of microdosers, the differences between individuals that only microdose and those that use both micro and macrodoses of psychedelics remain unexplored. In an online survey, we collected data of 6193 psychedelic consumers of which 2488 were microdosers of up to 11 different classical and atypical psychedelics.

View Article and Find Full Text PDF

One of the most important developments in psychopharmacology in the past decade has been the emergence of novel treatments for mood disorders, such as psilocybin for treatment-resistant depression. Psilocybin is most commonly found in different species of mushroom; however, the literature on mushroom and fungus extracts with potential antidepressant activity extends well beyond just psilocybin-containing mushrooms, and includes both psychedelic and non-psychedelic species. In the current review, we systematically review the preclinical literature on mushroom and fungus extracts, and their effects of animal models of depression and tests of antidepressant activity.

View Article and Find Full Text PDF

Disentangling the acute subjective effects of classic psychedelics from their enduring therapeutic properties.

Psychopharmacology (Berl)

May 2024

Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, 200 First Street, SW, Rochester, MN, 55905, USA.

Article Synopsis
  • Recent research highlights the therapeutic potential of classic psychedelics for neuropsychiatric disorders, emphasizing the role of personal insights gained during psychedelic sessions in achieving symptom resolution.
  • Strong correlations have been observed between the acute subjective effects (ASE) of psychedelics and their lasting therapeutic impacts, although challenges remain for widespread clinical use due to resource demands and limitations on patient eligibility.
  • Efforts are underway to find compounds that promote neuroplastic changes without inducing the hallucinogenic effects associated with classic psychedelics, leading to the discovery of 'non-psychedelic/subjective psychedelics' that maintain therapeutic efficacy.
View Article and Find Full Text PDF

Introduction: Recent research suggests that psychedelics may have potential for the treatment of various substance use disorders. However, most studies to date have been limited by small sample sizes and neglecting to include non-North American and European populations.

Methods: We conducted a global, cross-sectional online survey of adults (n = 5,268, 47.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!